Three years ago, we finalized our first CRISPR patent landscape analysis, at that time combined with an analysis of the TALE patent landscape which was then significantly larger. There were only 90 CRISPR patent families in this early analysis… that is less than the whole set of new CRISPR patent publications in the past single month: 116 additional patent families in our latest CRISPR patent analytics data set.
What is the latest IP situation of the People’s Republic of China in the CRISPR patent landscape? As announced in major media in April 2015, Chinese academic researchers have edited the genome of non-viable human embryos using the CRISPR/Cas9 system, triggering the on-going debates on human genome engineering ethical aspects. The presence of Chinese players, both academic and industrial, in the CRISPR patent landscape is also confirmed by our recent findings.